Deepika Lakhani - PAVmed Series Chief VP
| PAVMZ Stock | USD 0 0 30.00% |
VP
Deepika Lakhani is Chief VP of PAVmed Series Z
| Address | 360 Madison Avenue, New York, NY, United States, 10017 |
| Phone | (917) 813-1828 |
| Web | https://www.pavmed.com |
PAVmed Series Management Efficiency
The company has return on total asset (ROA) of (0.9591) % which means that it has lost $0.9591 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (13.5806) %, meaning that it generated substantial loss on money invested by shareholders. PAVmed Series' management efficiency ratios could be used to measure how well PAVmed Series manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 2.44 in 2025, whereas Return On Tangible Assets are likely to drop (1.91) in 2025. At this time, PAVmed Series' Non Current Assets Total are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.07 in 2025, whereas Total Assets are likely to drop slightly above 23.6 M in 2025.Similar Executives
| Found 4 records | VP Age | ||
| Jonathan JD | Mattel Inc | 56 | |
| Michael Ray | Micron Technology | 57 | |
| Fred Soulie | Mattel Inc | N/A | |
| Rene Casares | Academy Sports Outdoors | N/A | |
Management Performance
| Return On Equity | -13.58 | ||||
| Return On Asset | -0.96 |
PAVmed Series Z Leadership Team
Elected by the shareholders, the PAVmed Series' board of directors comprises two types of representatives: PAVmed Series inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PAVmed. The board's role is to monitor PAVmed Series' management team and ensure that shareholders' interests are well served. PAVmed Series' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PAVmed Series' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Gordon, General VP | ||
| Lishan MD, Chairman CEO | ||
| Michael Parks, Vice Relations | ||
| Deepika Lakhani, Chief VP | ||
| Shaun MBA, Executive COO | ||
| Brian MD, Chief VP | ||
| Victoria Lee, Senior Officer | ||
| Victoria MD, Senior Officer | ||
| Dennis CPA, CFO President |
PAVmed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PAVmed Series a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PAVmed Stock Analysis
When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.